FrancophonIA/ELRC3.0 huggingface dataset:
English: When using Palivizumab 100 mg/1 ml, the volume (expressed in ml) of Palivizumab to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Estonian: Palivisumab 100 mg/1 ml kasutamisel on palivisumabi maht (väljendatuna milliliitrites), mida tuleb manustada kord kuus = [patsiendi kehakaal kilogrammides] korrutatuna 0,15ga.
English: Allergic reactions including very rare cases of anaphylaxis and anaphylactic shock have been reported following palivizumab administration.
Estonian: Palivisumabi manustamise järgselt on kirjeldatud allergilisi reaktsioone, sealhulgas väga harvad anafülaksia ja anafülaktilise šoki juhud.
English: Reconstitute slowly with 1.0 ml water for injections.
Estonian: Lahustada aeglaselt 1,0 ml süsteveega.
English: Synagis 50 mg/0.5 ml solution for injection Synagis 100 mg/1 ml solution for injection Active substance: palivizumab
Estonian: Synagis 50 mg/0,5 ml süstelahus Synagis 100 mg/1 ml süstelahus Toimeaine: palivisumab (palivizumabum)
English: Medicinal products for the treatment of severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, should be available for immediate use following administration of palivizumab.
Estonian: Palivisumabi manustamise järgselt peavad koheseks kasutamiseks käepärast olema ravimid raskete ülitundlikkusreaktsioonide, kaasa arvatud anafülaksia ja anafülaktilise šoki raviks.
English: Label of 0.5 ml vial
Estonian: 0,5 ml viaali etikett
English: Please tell your doctor if your child is unwell, as the use of Synagis may need to be delayed.
Estonian: Palun informeerige arsti lapse haigusest, kuna vajalikuks võib osutuda
English: At least one of the palivizumab resistance-associated substitutions, N262D, K272E/Q, or S275F/L was identified in these 8 clinical RSV isolates resulting in a combined resistance-associated mutation frequency of 6.3% in these patients.
Estonian: Immunoprofülaktika ebaõnnestumise järgselt kogutud kliinilistest RSV isolaatidest tuvastati 8 juhul vähemalt üks palivisumabi resistentsust põhjustav asendus (N262D, K272E/Q või S275 F/L), mis annab kombineeritud resistentsust põhjustavate mutatsioonide esinemissageduseks 6,3%.
English: In an open label prospective trial designed to evaluate pharmacokinetics, safety and immunogenicity after administration of 7 doses of palivizumab within a single RSV season, pharmacokinetic data indicated that adequate mean palivizumab levels were achieved in all 18 children enrolled.
Estonian: Ühes avatud disainiga prospektiivses uuringus hinnati ühe RSV hooaja vältel enam kui 7 palivisumabi annust saanud patsientidelt kogutud farmakokineetika, ohutuse ja immunogeensuse andmeid.
English: Synagis 100 mg/1 ml solution for injection palivizumab
Estonian: Synagis 100 mg/1 ml süstelahus palivizumabum
English: Solvent for Synagis
Estonian: Synagis'e lahusti
English: Lyophilised formulation of palivizumab
Estonian: Palivisumabi lüofiliseeritud ravimvorm
English: 100 mg Outer Carton
Estonian: 100 mg välispakend
English: Synagis Water for injections ampoule label
Estonian: Synagis'e süstevee ampulli etikett
English: When using Palivizumab 100 mg/ml, the volume (expressed in ml) of Palivizumab to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Estonian: Palivisumab 100 mg/ml kasutamisel on palivisumabi maht (väljendatuna milliliitrites), mida tuleb manustada kord kuus = [patsiendi kehakaal kilogrammides] korrutatuna 0,15ga.
English: 50 mg Outer Carton
Estonian: 50 mg välispakend
English: Synagis 50 mg/0.5 ml solution for injection Synagis 100 mg/1 ml solution for injection
Estonian: Synagis, 50 mg/0.5 ml süstelahus Synagis, 100 mg/1 ml süstelahus
English: Transient, low levels of antipalivizumab antibody were observed in one child after the second dose of palivizumab that dropped to undetectable levels at the fifth and seventh dose.
Estonian: Ühel lapsel tekkisid pärast palivisumabi teise annuse manustamist ajutiselt ja madalas kontsentratsioonis palivisumabi-vastased antikehad.
English: One ml of Synagis solution for injection contains 100 mg of palivizumab.
Estonian: Üks ml Synagis süstelahust sisaldab 100 mg palivisumabi.
English: Outer Carton of 1.0 ml vial
Estonian: 1,0 ml viaali välispakend
English: - Each 0.5 ml vial contains 50 mg of palivizumab.
Estonian: - Üks 0,5 ml viaal sisaldab 50 mg palivisumabi.
English: The incidence of RSV hospitalisation was 16 of 612 (2.6%) in the palivizumab group.
Estonian: RSV tõttu hospitaliseerimiste sagedus oli palivisumabi rühmas 16 juhtu 612-st
English: Also contains: histidine, glycine and water for injections.
Estonian: Sisaldab ka histidiini, glütsiini ja süstevett.
English: Studies using lyophilised palivizumab
Estonian: Uuringud vedela palivisumabiga
English: Outer Carton of 0.5 ml vial
Estonian: 0,5 ml viaali välispakend
English: Each 0.5 ml vial contains 50 mg of palivizumab.
Estonian: Üks 0,5 ml viaal sisaldab 50 mg palivisumabi.
English: The results of the study indicate no increased risk of serious infection, serious arrhythmia, or death in children with HSCHD associated with Synagis prophylaxis compared with children who did not receive prophylaxis.
Estonian: Uuringu tulemused näitavad, et hemodünaamiliselt olulise kaasasündinud südamerikkega lastel, kes said profülaktikaks Synagis't, võrrelduna lastega, kes profülatikat ei saanud, ei esinenud kõrgemat raskete infektsioonide, raske arütmia või surma esinemissagedust.
English: This medicinal product should not be mixed with other medicinal products or diluents other than water for injections.
Estonian: Seda ravimit ei tohi segada teiste ravimite ega lahustitega peale süstevee.
English: The injection should be given using standard aseptic technique.
Estonian: Süstimisel järgida aseptikanõudeid.
English: Pre-term infants and children with Chronic Lung Disease of Prematurity (CLDP): this trial, conducted at 347 centers in the North America, European Union and 10 other countries, studied patients less than or equal to 24 months of age with CLDP and patients with premature birth (less than or equal to 35 weeks gestation) who were less than or equal to 6 months of age at study entry.
Estonian: Uuriti CLDP-ga patsiente vanuses 24 kuud või vähem ja enneaegselt sündinud patsiente (35 gestatsiooninädalat või vähem), kes olid uuringusse kaasamisel 6 kuu vanused või nooremad.
English: Nervous system disorders Uncommon
Estonian: Närvisüsteemi häired
English: Synagis 50 mg/0.5 ml solution for injection palivizumab
Estonian: Synagis 50 mg/0.5 ml süstelahus palivizumabum
English: Do not mix the palivizumab liquid and lyophilised formulations.
Estonian: Palivisumabi vedelat ja lüofiliseeritud ravimvormi ei tohi omavahel segada.
English: - Each 1 ml vial contains 100 mg of palivizumab.
Estonian: - Üks 1 ml viaal sisaldab 100 mg palivisumabi.
English: Palivizumab should not be mixed with any medicinal products or diluents other than water for injections.
Estonian: Palivisumabi ei tohi segada teiste ravimite ega lahustitega peale süstevee.
English: How will my child receive Synagis
Estonian: Kuidas Synagis't lapsel kasutada
English: Palivizumab binds a highly conserved region on the extracellular domain of mature RSV F protein, referred to as antigenic site II or A antigenic site, which encompasses amino acids 262 to 275.
Estonian: Palivisumab seondub küpse RS viiruse F-valgu ekstratsellulaarse domeeni kõrgelt konserveerunud osas, mida nimetatakse II antigeenseks e A-antigeenseks lõiguks.
English: Injection site reaction
Estonian: Palavik reaktsioonid
English: Synagis 100 mg powder and solvent for solution for injection Active substance: palivizumab
Estonian: Synagis 100 mg süstelahuse pulber ja lahusti Toimeaine: palivisumab (palivizumabum)
English: How to storeSynagis
Estonian: KG Knollstrasse
English: Synagis 50 mg powder and solvent for solution for injection Active substance: palivizumab
Estonian: Synagis 50 mg süstelahuse pulber ja lahusti Toimeaine: palivisumab (palivizumabum)
English: Each 1 ml vial contains 100 mg of palivizumab.
Estonian: Üks 1 ml viaal sisaldab 100 mg palivisumabi.
English: 1 vial Synagis 100 mg.
Estonian: 1 viaal Synagis 100 mg 1 ampull 1 ml süsteveega
English: 1 vial Synagis 50 mg.
Estonian: 1 viaal Synagis 50 mg 1 ampull 1 ml süsteveega
English: Swirl gently.
Estonian: Pöörata ettevaatlikult.
English: Liquid formulation of palivizumab
Estonian: Palivisumabi vedel ravimvorm
English: The volume (expressed in ml) of // Palivizumab // to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15.
Estonian: Palivisumabi maht (väljendatuna milliliitrites), mida tuleb manustada kord kuus = [patsiendi kehakaal kilogrammides] korrutatuna 0,15ga.
English: However, you should inform your doctor of all medicines your child is currently taking before starting Synagis.
Estonian: Teatage enne ravi alustamist Synagis'ega oma arstile, kui teie laps kasutab mis tahes muid ravimeid.
English: The active substance is palivizumab.
Estonian: Mida Synagis sisaldab - Toimeaine on palivisumab.
English: Each vial contains 50 mg palivizumab*, providing 100 mg/ml of palivizumab when reconstituted as recommended.
Estonian: Üks viaal sisaldab 50 mg palivisumabi* (palivizumabum), soovituste järgi valmistatud lahus sisaldab 100 mg/ml palivisumabi.
English: Each vial contains 100 mg palivizumab*, providing 100 mg/ml of palivizumab when reconstituted as recommended.
Estonian: Üks viaal sisaldab 100 mg palivisumabi* (palivizumabum), soovituste järgi valmistatud lahus sisaldab 100 mg/ml palivisumabi.
English: Synagis 100 mg powder for solution for injection palivizumab
Estonian: Synagis 100 mg süstelahuse pulber ja lahusti palivizumabum
English: - The other ingredients are histidine, glycine and water for injections.
Estonian: - Abiained on histidiin, glütsiin ja süstevesi.
English: Synagis 50 mg powder for solution for injection palivizumab
Estonian: Synagis 50 mg süstelahuse pulber ja lahusti palivizumabum
English: Each vial contains 50 mg palivizumab, providing 100 mg/ml of palivizumab when reconstituted as recommended.
Estonian: Üks viaal sisaldab 50 mg palivisumabi, soovituste järgi valmistatud lahus sisaldab 100 mg/ml palivisumabi.
English: How will my child receive Synagis?
Estonian: Kuidas Synagis't manustatakse?
English: In an open label prospective trial designed to evaluate pharmacokinetics, safety, and immunogenicity after administration of 7 doses of palivizumab within a single RSV season, pharmacokinetic data indicated that adequate mean palivizumab levels were achieved in all 18 children enrolled.
Estonian: Farmakokineetika osas ilmnes, et kõigil 18-l uuringusse kaasatud lapsel saavutati piisavad keskmised palivisumabi tasemed.
English: Histidine Glycine
Estonian: Histidiin Glütsiin Süstevesi
English: Solvent: Water for injections
Estonian: Lahusti: Süstevesi
English: Synagis 100 mg powder and solvent for solution for injection
Estonian: Synagis, 100 mg süstelahuse pulber ja lahusti
English: Each vial contains: 100 mg palivizumab, providing 100 mg/ml of palivizumab when reconstituted as recommended.
Estonian: Üks viaal sisaldab 100 mg palivisumabi, soovituste järgi valmistatud lahus sisaldab 100 mg/ml palivisumabi.
English: Synagis 50 mg powder and solvent for solution for injection
Estonian: Synagis 50 mg süstelahuse pulber ja lahusti
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tekturna to Novartis Europharm Limited on 22 August 2007.
Estonian: Euroopa Komisjon andis Tekturna müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Novartis Europharm Limited 22. augustil 2007.
English: The Committee recommended that Tekturna be given marketing authorisation.
Estonian: Komitee soovitas anda Tekturnale müügiloa.
English: Tekturna is not recommended for use in patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group.
Estonian: Tekturnat ei soovitata kasutada alla 18 aasta vanustel patsientidel, sest ohutuse ja efektiivsuse andmed selle vanuserühma kohta puuduvad.
English: Other information about Tekturna:
Estonian: Muu teave Tekturna kohta
English: Tekturna was studied in 14 main studies involving over 10,000 patients with essential hypertension.
Estonian: Tekturna kasutamist uuriti 14 põhiuuringus, milles osales rohkem kui 10 000 essentsiaalse hüpertensiooniga patsienti.
English: The studies also showed that Tekturna, when taken in combination with other medicines (especially hydrochlorothiazide), can produce additional decreases in blood pressure compared with the decreases produced by these medicines when they are taken without Tekturna.
Estonian: Uuringud näitasid ka, et Tekturna kasutamisel koos teiste ravimitega (eriti hüdroklorotiasiidiga) võib vererõhk väheneda enamgi, võrreldes vähenemisega nende ravimite kasutamisel ilma Tekturnata.
English: The recommended dose of Tekturna is 150 mg once a day, either taken alone or in combination with other medicines for hypertension.
Estonian: Tekturna soovituslik annus on 150 mg üks kord päevas kas ainsa ravimina või koos teiste kõrgvererõhuravimitega.
English: Tekturna also reduced blood pressure in patients with diabetes and patients who were overweight.
Estonian: Tekturna vähendas vererõhku ka diabeediga või ülekaalulistel patsientidel.
English: When the results of the five studies comparing Tekturna taken alone with placebo were looked at together, patients aged under 65 years had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Tekturna, from an average of 99.4 mmHg at the start of the study.
Estonian: Viie uuringu kokkuvõttes, milles võrreldi Tekturna kasutamist ainsa ravimina platseebo kasutamisega, vähenes alla 65 aasta vanuste patsientide diastoolne vererõhk pärast 150 mg Tekturna kasutamist kaheksa nädala jooksul keskmiselt 9,0 mm Hg võrra, võrreldes keskmise rõhuga 99,4 mm Hg ravi algul.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Tekturna are greater than its risks for the treatment of essential hypertension.
Estonian: Inimravimite komitee otsustas, et Tekturna kasulikkus essentsiaalse hüpertensiooni ravis on suurem kui ravimiga kaasnevad riskid.
English: Tekturna is used to treat essential hypertension (high blood pressure).
Estonian: Tekturnat kasutatakse essentsiaalse hüpertensiooni (kõrge vererõhu) raviks.
English: The most common side effect with Tekturna (seen in between 1 and 10 patients in 100) is diarrhoea.
Estonian: Tekturna kõige sagedam kõrvalnäht (esinenud ühel kuni kümnel patsiendil sajast) on kõhulahtisus.
English: What is the risk associated with Tekturna?
Estonian: Mis riskid Tekturnaga kaasnevad?
English: Combination studies looked at Tekturna used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide).
Estonian: Ravimikombinatsioonide uuringutes vaadeldi Tekturna kasutamist koos angiotensiini muundava ensüümi inhibiitoriga (ramipriil), angiotensiini retseptorit blokeeriva ainega (valsartaan), beetablokaatoriga (atenolool), kaltsiumikanalit blokeeriva ainega (amlodipiin) ja diureetikumiga (hüdroklorotiasiid).
English: The studies lasted between six and 52 weeks and the main measure of effectiveness was the change in blood pressure during either the resting phase of the heartbeat (diastolic) or when the chambers of the heart were contracting (systolic).
Estonian: Uuringute kestus oli 6-52 nädalat ja nende efektiivsust mõõdeti põhiliselt kas südame puhkefaasis või südame kokkutõmbumise ajal mõõdetud vererõhus (vastavalt diastoolne ja süstoolne vererõhk) toimunud muutuste järgi.
English: In five of the studies, the effects of Tekturna taken alone were compared with those of placebo (a dummy treatment).
Estonian: Viies uuringus võrreldi Tekturna toimet selle kasutamisel ainsa ravimina platseebo (näiva ravimi) toimega.
English: Why has Tekturna been approved?
Estonian: Miks Tekturna heaks kiideti?
English: For the full list of all side effects reported with Tekturna, see the Package Leaflet.
Estonian: Tekturna kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Tekturna should not be used by people who may be hypersensitive (allergic) to aliskiren or any of the other ingredients.
Estonian: Tekturnat ei tohi kasutada patsiendid, kes võivad olla aliskireeni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Tekturna is a medicine that contains the active substance aliskiren.
Estonian: Tekturna on ravim, mis sisaldab toimeainena aliskireeni.
English: The active substance in Tekturna, aliskiren, is a renin inhibitor.
Estonian: Tekturnas toimeainena sisalduv aliskireen on reniini inhibiitor.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TEKTURNA EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE TEKTURNA Kokkuvõte üldsusele
English: Tekturna, taken alone or in combination with other medicines, was also compared with other medicines for hypertension.
Estonian: Tekturna kasutamist ainsa ravimina või koos teiste ravimitega võrreldi ka teiste kõrgvererõhuravimite kasutamisega.
English: What is Tekturna?
Estonian: Mis on Tekturna?
English: Tekturna must also not be taken with ciclosporin (a medicine that reduces the activity of the immune system), quinidine (used to correct irregular heartbeat) or verapamil (used to treat heart problems).
Estonian: Tekturnat ei tohi manustada koos tsüklosporiiniga (immuunsüsteemi talitlust vähendav ravim), kinidiiniga (südame rütmihäirete ravim) ega verapamiiliga (südameravim).
English: It must not be in patients who have had angioedema (swelling under the skin) with aliskiren or in women who are more than three months pregnant.
Estonian: Ravimit ei tohi kasutada patsientidel, kellel on aliskireeni korral olnud angioödeem (nahaalune turse), ega rasedatel pärast esimest kolme raseduskuud.
English: The effects of Tekturna were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Tekturna toimet muude katsetega.
English: The full EPAR for Tekturna can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Tekturna kohta leiate siit.
English: What is Tekturna used for?
Estonian: Milleks Tekturnat kasutatakse?
English: What benefit has Tekturna shown during the studies?
Estonian: Milles seisneb uuringute põhjal Tekturna kasulikkus?
English: How has Tekturna been studied?
Estonian: Kuidas Tekturnat uuriti?
English: It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Tekturna.
Estonian: Seda manustatakse koos kerge einega, eelistatavalt iga päev samal kellaajal.
English: How is Tekturna used?
Estonian: Kuidas Tekturnat kasutatakse?
English: Tekturna on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Estonian: Tekturna vähendas kasutamisel ainsa ravimina vererõhku efektiivsemini kui platseebo ja sama efektiivselt kui võrdlusravimid.
English: How does Tekturna work?
Estonian: Kuidas Tekturna toimib?
English: Larger falls were seen in patients aged 65 years or over and those taking higher doses of Tekturna.
Estonian: Vähemalt 65-aastastel patsientidel ja Tekturnat suuremates annustes kasutanud patsientidel vähenes vererõhk rohkem.
English: The dose of Tekturna may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Estonian: Patsientidel, kelle vererõhk ravile piisavalt ei allu, võib Tekturna annust suurendada annuseni 300 mg üks kord päevas.
English: Do not use in pregnant animals, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Estonian: Mitte kasutada tiinetel loomadel, kelle piima plaanitakse tarvitada inimtoiduks 2 kuud enne oodatavat poegimist.
English: Content Package size
Estonian: Pakend i suurus
English: Each transdermal patch releases 203 micrograms of NGMN and 33.9 micrograms of EE per 24 h.
Estonian: Iga transdermaalne plaaster vabastab 203 mikrogrammi NGMN-i ja 33,9 mikrogrammi EE-d 24 tunni jooksul.
English: Each transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
Estonian: Iga transdermaalne plaaster sisaldab 6 mg norelgestromiini (NGMN) ja 600 mikrogrammi etinüülöstradiooli (EE).
English: Strength Pharmaceutical Form Route of Administration
Estonian: Müügiloa nr Euroopa Liidus Ravimi väljamõeldud nimetus
English: Packaging Content Package size
Estonian: Tugevus Ravimvorm Loomaliigid Manustamisviis Pakend Sisaldus Pakendi suurus Keeluaeg
English: The same place must not be used again until at least seven days later.
Estonian: Sama kohta tohib kasutada alles vähemalt 7 päeva pärast.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Intrinsa on 28 July 2006.
Estonian: Euroopa Komisjon andis Intrinsa müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. juulil 2006.
English: Intrinsa testosterone
Estonian: Intrinsa testosteroon
English: The company will also provide an educational plan for doctors and patients.
Estonian: Tootja esitab teabekava arstidele ja patsientidele.
English: The patch remains on the skin for three or four days and is then replaced by a new patch in a different place.
Estonian: Plaaster jäetakse nahale 3-4 päevaks ning asendatakse siis teises kohas uuega.
English: If a patient does not feel any improvement after three to six months of treatment, she should contact her doctor and have her treatment reviewed.
Estonian: Kui patsiendi seisund ei parane 3-6kuulise ravi järel, peab ta pöörduma arsti poole, et tema ravi uuesti läbi vaadataks.
English: It may take longer than a month for the patient to feel an improvement.
Estonian: Patsiendi seisundi parenemiseks võib kuluda rohkem kui kuu.
English: The main measure of effectiveness was based on the change in the questionnaire score before the study began and after six months of treatment.
Estonian: Efektiivsuse põhinäitaja oli küsimustiku punktide arvus toimunud muutus võrrelduna uuringu eel ja pärast 6-kuulist ravi.
English: Intrinsa is used as a continuous treatment, as one patch twice a week.
Estonian: Intrinsat kasutatakse pideva ravina, üks plaaster kaks korda nädalas.
English: Because testosterone is a well-known substance that is already used in other medicines, the company used data from the published literature as well as carrying out studies itself.
Estonian: Kuna testosteroon on tuntud toimeaine, mida kasutatakse ka teistes ravimites, kasutas ettevõte peale oma uuringute ka kirjanduses avaldatud andmeid.
English: The CHMP decided that Intrinsa's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Intrinsa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: This document is a summary of the European public assessment report (EPAR) for Intrinsa.
Estonian: Käesolev dokument on ravimi Intrinsa Euroopa avaliku hindamisaruande kokkuvõte.
English: The two main studies involved 1,095 women with an average age of 49 years who received Intrinsa for up to a year.
Estonian: Kahes Intrinsa efektiivsuse põhiuuringus osales 1095 naist (keskmine vanus 49 aastat), kes kasutasid Intrinsat kuni ühe aasta jooksul.
English: Other information about Intrinsa:
Estonian: Muu teave Intrinsa kohta
English: The marketing authorisation holder is Warner Chilcott UK Ltd.
Estonian: Müügiloa hoidja on Warner Chilcott UK Ltd. Müügiluba kehtib viis aastat ja seda on võimalik pikendada.
English: It is used in patients already taking an oestrogen (a female
Estonian: Seda kasutatakse patsientidel, kes kasutavad juba östrogeeni (naissuguhormoon).
English: It must not be used in women who have or have had breast cancer or another oestrogen-dependent cancer, or who have other conditions that mean that they cannot take oestrogen-containing medicines.
Estonian: Ravimit ei tohi kasutada ka naised, kellel on olnud rinnavähk või muu östrogeenist sõltuv vähivorm või muud seisundid, mille tõttu nad ei saa kasutada östrogeeni sisaldavaid ravimeid.